story of the week
Effect of SGLT2 Inhibitors on Major Adverse Cardiovascular Outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
Circulation 2024 Apr 07;[EPub Ahead of Print], SM Patel, YM Kang, K Im, BL Neuen, SD Anker, DL Bhatt, J Butler, DZI Cherney, BL Claggett, RA Fletcher, WG Herrington, SE Inzucchi, MJ Jardine, KW Mahaffey, DK McGuire, JJV McMurray, B Neal, M Packer, V Perkovic, SD Solomon, N Staplin, M Vaduganathan, C Wanner, DC Wheeler, F Zannad, Y Zhao, HJL Heerspink, MS Sabatine, SD WiviottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.